Mark J. Ratain to Topoisomerase I Inhibitors
This is a "connection" page, showing publications Mark J. Ratain has written about Topoisomerase I Inhibitors.
Connection Strength
0.537
-
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. AAPS J. 2020 03 17; 22(3):59.
Score: 0.186
-
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997 Apr; 15(4):1502-10.
Score: 0.152
-
Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
Score: 0.071
-
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
Score: 0.061
-
Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov; 8(6):525-34.
Score: 0.037
-
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004 Apr 15; 22(8):1439-46.
Score: 0.015
-
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002 Dec; 12(9):725-33.
Score: 0.014